ORG
Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns
Sarepta Therapeutics; Elevidys; Q2 2025; gene therapy; sales performance; FDA; safety issues; shipment pause
Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program
Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development
Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027
Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline
FDA Grants Accelerated Approval to Jazz’s Dordaviprone (Modeyso), the First Treatment for Ultra-Rare Brain Tumor
Dordaviprone; Modeyso; FDA approval; H3 K27M-mutant diffuse midline glioma; ultra-rare brain tumor; Jazz Pharmaceuticals; accelerated approval; pediatric brain cancer; Chimerix acquisition; confirmatory trial
Execution, Execution, Execution: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline
Novo Nordisk; Maziar Mike Doustdar; obesity; diabetes; pipeline cuts; GLP-1 drugs; Wegovy; Ozempic; incretin market; leadership change
XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration
XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties
BioNTech to Cut 90 More US Jobs Amid Strategic Realignment
BioNTech; layoffs; job cuts; R&D; pipeline focus; Gaithersburg; Cambridge; cell therapy; post-COVID market; strategic alignment
HHS Ends BARDA Funding for Future mRNA Vaccine Development, Citing Efficacy Concerns
mRNA vaccines; BARDA; Robert F. Kennedy Jr.; vaccine efficacy; HHS; COVID-19; flu; project cancellation; public health policy
Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift
Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition
Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring
Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry